{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:58:17Z","timestamp":1769122697083,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T00:00:00Z","timestamp":1399593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s11239-014-1082-5","type":"journal-article","created":{"date-parts":[[2014,5,8]],"date-time":"2014-05-08T11:44:37Z","timestamp":1399549477000},"page":"269-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests"],"prefix":"10.1007","volume":"38","author":[{"given":"Giuseppe","family":"Lippi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ardissino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Quintavalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Cervellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,9]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11239-009-0307-5","volume":"27","author":"RC Becker","year":"2009","unstructured":"Becker RC (2009) Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. J Thromb Thrombolysis 27:119\u2013121","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11239-013-0869-0","volume":"36","author":"GM Bernacki","year":"2013","unstructured":"Bernacki GM, Becker RC (2013) Oral anticoagulants in older adults with atrial fibrillation. J Thromb Thrombolysis 36:403\u2013415","journal-title":"J Thromb Thrombolysis"},{"issue":"2 Suppl","key":"1082_CR3","first-page":"e531S","volume":"141","author":"JJ You","year":"2012","unstructured":"You JJ, DE Singer, Howard PA, American College of Chest Physicians et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e531S\u2013e575S","journal-title":"Chest"},{"key":"1082_CR4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11239-013-0911-2","volume":"36","author":"G Connolly","year":"2013","unstructured":"Connolly G, Spyropoulos AC (2013) Practical issues, limitations, and periprocedural management of the NOAC\u2019s. J Thromb Thrombolysis 36:212\u2013222","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.11613\/BM.2012.035","volume":"22","author":"EJ Favaloro","year":"2012","unstructured":"Favaloro EJ, Lippi G (2012) The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 22:329\u2013341","journal-title":"Biochem Med (Zagreb)"},{"key":"1082_CR6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11239-013-0967-z","volume":"37","author":"TA Dewald","year":"2014","unstructured":"Dewald TA, Becker RC (2014) The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 37:217\u2013233","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"1082_CR7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11239-013-0958-0","volume":"37","author":"LR Jackson 2nd","year":"2014","unstructured":"Jackson LR 2nd, Becker RC (2014) Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis 37(3):380\u2013391","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11239-013-0956-2","volume":"36","author":"SD Pokorney","year":"2013","unstructured":"Pokorney SD, Sherwood MW, Becker RC (2013) Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis 36:163\u2013174","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR9","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","volume":"2013","author":"A G\u00f3mez-Outes","year":"2013","unstructured":"G\u00f3mez-Outes A, Terleira-Fern\u00e1ndez AI, Calvo-Rojas G, Su\u00e1rez-Gea ML, Vargas-Castrill\u00f3n E (2013) Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis 2013:640723","journal-title":"Thrombosis"},{"key":"1082_CR10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/heartjnl-2013-304347","volume":"100","author":"A Dogliotti","year":"2014","unstructured":"Dogliotti A, Paolasso E, Giugliano RP (2014) Current and new oral antithrombotics in nonvalvular atrial fibrillation: a network meta-analysis of 79,808 patients. Heart 100:396\u2013405","journal-title":"Heart"},{"key":"1082_CR11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","unstructured":"The Hokusai-VTE Investigators (2013) Edoxaban versus Warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415","journal-title":"N Engl J Med"},{"key":"1082_CR12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, AMPLIFY Investigators et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799\u2013808","journal-title":"N Engl J Med"},{"key":"1082_CR13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","volume":"368","author":"AT Cohen","year":"2013","unstructured":"Cohen AT, Spiro TE, B\u00fcller HR, MAGELLAN Investigators et al (2013) Rivaroxaban for thromboprophylaxis in acutely Ill medical patients. N Engl J Med 368:513\u2013523","journal-title":"N Engl J Med"},{"key":"1082_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11239-013-0929-5","volume":"36","author":"KP Cabral","year":"2013","unstructured":"Cabral KP (2013) Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis 36:133\u2013140","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1515\/CCLM.2011.126","volume":"49","author":"EJ Favaloro","year":"2011","unstructured":"Favaloro EJ, Lippi G (2011) Laboratory testing and\/or monitoring of the new oral anticoagulants\/antithrombotics: for and against? Clin Chem Lab Med 49:755\u2013757","journal-title":"Clin Chem Lab Med"},{"key":"1082_CR16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11239-013-0880-5","volume":"35","author":"BA Konkle","year":"2013","unstructured":"Konkle BA (2013) Monitoring target specific anticoagulants. J Thromb Thrombolysis 35:387\u2013390","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR17","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1515\/cclm-2012-0327","volume":"50","author":"A Tripodi","year":"2012","unstructured":"Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C (2012) Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL. Clin Chem Lab Med 50:2137\u20132140","journal-title":"Clin Chem Lab Med"},{"key":"1082_CR18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11239-012-0781-z","volume":"34","author":"KL Carter","year":"2012","unstructured":"Carter KL, Streiff MB, Ross PA et al (2012) Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital. J Thromb Thrombolysis 34:437\u2013445","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","volume":"34","author":"DM Siegal","year":"2013","unstructured":"Siegal DM, Crowther MA (2013) Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 34:489\u2013498b","journal-title":"Eur Heart J"},{"key":"1082_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11239-013-0907-y","volume":"36","author":"H Mani","year":"2013","unstructured":"Mani H, Kasper A, Lindhoff-Last E (2013) Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 36:187\u2013194","journal-title":"J Thromb Thrombolysis"},{"key":"1082_CR21","first-page":"1501","volume":"50","author":"A Tripodi","year":"2012","unstructured":"Tripodi A (2012) Interference of new oral anticoagulants with frequently used coagulation tests. Clin Chem Lab Med 50:1501\u20131503","journal-title":"Clin Chem Lab Med"},{"key":"1082_CR22","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.reprotox.2006.02.001","volume":"21","author":"E Mendelson","year":"2006","unstructured":"Mendelson E, Aboudy Y, Smetana Z, Tepperberg M, Grossman Z (2006) Laboratory assessment and diagnosis of congenital viral infections: rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus (HSV), parvovirus B19 and human immunodeficiency virus (HIV). Reprod Toxicol 21:350\u2013382","journal-title":"Reprod Toxicol"},{"key":"1082_CR23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/10550887.2010.509277","volume":"29","author":"PL Tenore","year":"2010","unstructured":"Tenore PL (2010) Advanced urine toxicology testing. J Addict Dis 29:436\u2013448","journal-title":"J Addict Dis"},{"key":"1082_CR24","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","volume":"59","author":"R Caterina De","year":"2012","unstructured":"De Caterina R, Husted S, Wallentin L, Coordinating Committee et al (2012) New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 59:1413\u20131425","journal-title":"J Am Coll Cardiol"},{"key":"1082_CR25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12052","volume":"159","author":"T Baglin","year":"2012","unstructured":"Baglin T, Keeling D, Kitchen S, British Committee for Standards in Haematology (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 159:427\u2013429","journal-title":"Br J Haematol"},{"key":"1082_CR26","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","volume":"34","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M et al (2013) EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 34:2094\u20132106","journal-title":"Eur Heart J"},{"key":"1082_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1477-9560-11-27","volume":"11","author":"C Ward","year":"2013","unstructured":"Ward C, Conner G, Donnan G, Gallus A, McRae S (2013) Practical management of patients on apixaban: a consensus guide. Thromb J 11:27","journal-title":"Thromb J"},{"key":"1082_CR28","unstructured":"Swedish Society on Thrombosis and Haemostasis (SSTH). Clinical recommendations for treatment with new oral anticoagulants. Available at: http:\/\/ssth.se\/documents\/vp\/vpeng120213.pdf . Last access: 20 Feb 2014"},{"key":"1082_CR29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","volume":"107","author":"J Douxfils","year":"2012","unstructured":"Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogn\u00e9 JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107:985\u2013997","journal-title":"Thromb Haemost"},{"key":"1082_CR30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","volume":"130","author":"J Douxfils","year":"2012","unstructured":"Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogn\u00e9 JM (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130:956\u2013966","journal-title":"Thromb Res"},{"key":"1082_CR31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","volume":"110","author":"J Douxfils","year":"2013","unstructured":"Douxfils J, Chatelain C, Chatelain B, Dogn\u00e9 JM, Mullier F (2013) Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 110:283\u2013294","journal-title":"Thromb Haemost"},{"key":"1082_CR32","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","volume":"34","author":"BP Krijthe","year":"2013","unstructured":"Krijthe BP, Kunst A, Benjamin EJ et al (2013) Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34:2746\u20132751","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-014-1082-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-014-1082-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-014-1082-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T23:27:22Z","timestamp":1689204442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-014-1082-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,9]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s11239-014-1082-5","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,9]]}}}